19Aug/13

Illumina Launches New Reagent Kits for the MiSeq® System – DailyFinance

Illumina Launches New Reagent Kits for the MiSeq® System
DailyFinance
The benefits of increased paired-end read lengths include improving the quality of genome assemblies and advancing applications that require longer read lengths, such as metagenomics and human leukocyte antigen (HLA) typing. “The new MiSeq kits are 
Illumina launches new reagent kits for MiSeq benchtop sequencerPharmaceutical Business Review

all 3 news articles »

19Aug/13

Heart's Own Stem Cells Can Be Used To Treat Heart Failure: Study – Headlines & Global News


Headlines & Global News

Heart’s Own Stem Cells Can Be Used To Treat Heart Failure: Study
Headlines & Global News
Heart Failure is the cause of 287,000 deaths a year with over 5 million Americans currently living with some form of heart diseases. Approximately, 550,000 new cases are diagnosed in the U.S. each year with this disease being the leading cause of death
Heart’s own stem cells could help treat cardiac failureIndia.Com Health

all 2 news articles »

19Aug/13

German organ donor scandal doctor goes on trial – BBC News


BBC News

German organ donor scandal doctor goes on trial
BBC News
A doctor accused of falsifying patients’ information to push them up an organ transplant list goes on trial in Germany on Monday. It is alleged the doctor falsified information in at least 25 cases, and accepted money from multiple patients outside
Donor scandal doctor blasts ‘absurd’ chargesThe Local.de
Organ transplant fraud trial opens in GermanyDeutsche Welle

all 5 news articles »

19Aug/13

Children's Cancer Recovery Foundation Reveals New Antibodies that May Fight … – DigitalJournal.com

Children’s Cancer Recovery Foundation Reveals New Antibodies that May Fight
DigitalJournal.com
The article explains that they “have developed two monoclonal antibodies called anti-4-1BB and anti-CD40 and investigated a third called anti-CTLA-4.” The antibodies bind to different molecules in the immune system and stimulate its response in

and more »